Thursday, October 6, 2022

Latest Posts

Leuko Raises $5 Million Collection A to Validate and Deliver to Market Its Noninvasive White Blood Cell Monitoring Know-how for Most cancers Sufferers

BOSTON–(BUSINESS WIRE)–Leuko, an MIT startup growing PointCheckTM, the primary resolution that allows at-home noninvasive white blood cell (WBC) monitoring, right this moment introduced a primary closing of $5 million for his or her Collection A spherical. The brand new funding, from HTH VC, Good Development Capital, IAG Capital Companions, Nina Capital, and angel traders, will speed up Leuko’s scientific trials to acquire regulatory approval in collaboration with main most cancers facilities, together with Boston Medical Middle and MD Anderson within the USA, and Dexeus and Hospital 12 de Octubre in Europe. Leuko may even proceed to pursue its go-to-market and partnership actions with healthcare suppliers, medical system distributors and pharmaceutical firms.

“Low WBC ranges is likely one of the commonest in addition to most devastating and costliest unwanted effects of most cancers chemotherapy. Scientific information signifies that as many as one out of each six chemotherapy sufferers endure life-threatening infections and hospital readmissions instantly linked to low WBCs,” mentioned Leuko co-founder and CEO Dr. Carlos Castro-Gonzalez. “At Leuko, we’re engaged on an answer to assist sufferers and suppliers stop these hospital readmissions and enhance scientific outcomes, by remotely monitoring WBC ranges earlier than infections ensue.”

With Leuko, sufferers merely place their finger onto an web linked PointCheckTM system for simply 1 minute a day. The system measures WBC ranges and not using a blood pattern draw. The info is shipped to the affected person’s care crew, which may triage findings to assist sufferers obtain acceptable, preventive therapies underneath the path of their clinician. The know-how has demonstrated wonderful diagnostic accuracy and residential usability in latest peer-reviewed research.

“We’re excited to assist Leuko as they scale and produce this clinically validated resolution to the thousands and thousands of sufferers who can reside more healthy lives by an elevated monitoring of their weakened immune system,” mentioned Michele Gaiotto, CEO of HTH VC, who leads the Firm Collection A. “We imagine that Leuko is constructing a robust crew and know-how platform and are honored to assist its worthy mission.”

Amy Salzhauer, Managing Accomplice of Good Development Capital, who led the Firm Collection Seed, mentioned “We proceed to be impressed by the potential worth delivered by the PointCheckTM platform, which has been achieved by integrating proprietary distant monitoring know-how in a product that can be utilized by unsupervised sufferers at residence.”

About Leuko

Leuko is a startup spun out from MIT and the Madrid M+Imaginative and prescient Consortium and based by Carlos Castro-Gonzalez, Ian Butterworth, Aurelien Bourquard, and Alvaro Sanchez-Ferro. They’re growing a platform know-how, PointCheckTM, that mixes optics and AI to make noninvasive blood testing simpler, sooner and extra accessible than state-of-the artwork options. For its first utility, Leuko goals to enhance scientific outcomes for >2M most cancers chemotherapy sufferers a yr, cut back their chemotherapy-related hospital readmissions by 50% and save >$6B yearly in healthcare price. For extra data, go to or observe us on Twitter @leuko.

About HTH VC

HTH is a full-fledged funding and advisory firm investing alongside shiny innovators devoted to bettering people’ well being. Born in 2020, HTH enhances ZCube-Zambon Analysis Enterprise scouting and investing actions with direct participation in early-stage deep tech startups devoted to bettering human lives.

About Good Development Capital

Good Development Capital is a majority girls and minority-managed early-stage enterprise capital agency that funds transformative start-ups in sectors together with biomed tech, inexperienced tech and information sciences. Good Development Capital and its funds meet each ESG and UNSDG impression objectives.

Related:  Can Indian SSIs Flourish In A SAAS World-Srinath Sridharan

Latest Posts

Don't Miss

Stay in touch

To be updated with all the latest news, offers and special announcements.